Kalkine has a fully transformed New Avatar.

blue-chip

One Health Care Equipment & Services Stock Trading Near Resistance Levels – RMD

Jul 26, 2024 | Team Kalkine
One Health Care Equipment & Services Stock Trading Near Resistance Levels – RMD

RMD:ASX
Investment Type
Large-cap
Risk Level
Action
Rec. Price (AU$)

ResMed Inc. (ASX: RMD)

RMD is a provider of digital health technologies and cloud-connected medical devices. The products and solutions are designed for people with sleep apnea, chronic obstructive pulmonary disease (COPD), and other chronic diseases.

Recommendation Rationale – SELL at AUD 31.84

  • Trading Around Resistance: RMD’s share price surpassed its R1 level recommended on 3 July 2024.
  • Overvalued Multiples: On a forward 12-month basis, the stock is trading at an EV/Sales multiple of 6.0x vs industry (Healthcare) median of 3.3sx.
  • Rising Costs: During 3QFY24 for the period ended 31 March 2024, the company noted increased operating expenses attributed to higher selling, general, and administrative expenses, R&D expenditure, among others. These factors are expected to exert downward pressure on its margins in the future.
  • Leveraged Balance Sheet: As of 31 March 2024, Long-term debt stood at USD 997mn compared with USD 1,216.7mn as of 31 December 2023. Cash balances amounted to USD 237.9mn as of 31 March 2024. Although the debt level was sequentially lower, it is still on the higher side compared to RMD’s cash balance.
  • Emerging Risks: RMD continues to prioritise product development and innovation in sleep apnea and respiratory care, ensuring cutting-edge solutions that meet evolving healthcare needs.

RMD Daily Chart

(Source: Trading View)

Valuation Methodology: P/E Approach (FY June'25E) (Illustrative)

Stock might trade at a slight premium to its peers, considering the company’s consistent revenue growth and profitability, increasing adoption and demand for its products and solutions, and other factors. For valuation, few peers like Ansell Ltd (ASX: ANN), Sonic Healthcare Ltd (ASX: SHL), and Ramsay Health Care Ltd (ASX: RHC) have been considered. Considering that the stock has surpassed its R1 level, share price movement, other risks associated with the business, and downside indicated by the valuation, it can face resistance at the current levels. Hence, a ‘Sell’ recommendation is given on the stock at the current market price of AUD 31.84, as of 26 July 2024, at 10:05 AM AEST.

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and geopolitical issues prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Note 1: Past performance is neither an indicator nor a guarantee of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance levels is 26 July 2024. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Technical Indicators Defined: -

Support: A level at which the stock prices tend to find support if they are falling, and downtrend may take a pause backed by demand or buying interest.

Resistance: A level at which the stock prices tend to find resistance when they are rising, and uptrend may take a pause due to profit booking or selling interest.

Stop-loss: In general, it is a level to protect further losses in case of any unfavourable movement in the stock prices.


Disclaimer-

This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider seeking advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice. The information in this report does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products. Our reports contain general recommendations to invest in securities and other financial products.

Kalkine is not responsible for, and does not guarantee, the performance of the investments mentioned in this report This report may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services..

Please also read our Terms & Conditions and Financial Services Guide for further information. Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this report or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website including entities covered in this Report.